Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $40.03 (market cap $135.56M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 37× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 62 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GPTY | TVTX | |
|---|---|---|
Market Cap | $135.56M | $5.02B |
Volume | 66,044 | 2,060,842 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $67.52 |
52-Week Low | $34.73 | $26.79 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY, a US stock, trades at $42.44, up 0.05% in the last 24 hours. The technical outlook is bearish based on moving averages, with key support at $42 and resistance at $43. Recent news highlights the ETF's weekly dividend distributions and a Seeking Alpha article from August 2026 rating it a Buy for high AI-driven income, citing its covered call spread strategy.
The outlook for GPTY is mixed, with a high-yield income opportunity from consistent dividends but tempered by bearish technical signals and limited fundamental data. Risks include market volatility and dependence on options strategies, while institutional interest remains a potential catalyst.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
